Opioid Analgesia in Acute Myocardial Infarction: Pharmacokinetic Interaction with P2Y12 Inhibitors and Pharmacodynamic Consequences-A Clinical Review for Emergency Physicians.

BACKGROUND

Opioids still have a role in treating severe ischemic pain during acute myocardial infarction. Their gastrointestinal effects, however, may slow absorption of oral P2Y12 inhibitors and postpone platelet inhibition at a time when antiplatelet loading and percutaneous coronary intervention often occur close together.

OBJECTIVE(S): This clinical review examines the pharmacokinetic basis and pharmacodynamic consequences of the opioid-P2Y12 interaction, the uncertainty surrounding clinical outcomes, and the practical implications for emergency and prehospital care.

DISCUSSION: Randomized pharmacology studies show altered early exposure to clopidogrel, prasugrel, and ticagrelor after morphine, although the prasugrel effect was limited to a lower maximum active-metabolite concentration in healthy volunteers. Fentanyl also delays ticagrelor compared with no opioid, but the small head-to-head comparison with morphine was inconclusive. Trials of alternative formulations, prokinetic treatment, peripheral opioid antagonism, and opioid-sparing analgesia have largely measured drug exposure, platelet reactivity, or pain. None was powered to determine mortality, reinfarction, or stent thrombosis, and observational outcome studies remain difficult to interpret because opioid-treated patients are often sicker at baseline.

CONCLUSIONS

In practice, pain relief should proceed alongside diagnosis and reperfusion. Nitroglycerin is appropriate when hemodynamics allow; an opioid is reasonable for severe pain that persists despite tolerated anti-ischemic therapy or when nitrates cannot be used. Small titrated doses, reassessment before redosing, and clear communication of opioid exposure, vomiting, shock, and P2Y12 loading time are more defensible than routine administration.